Histone Deacetylase Inhibition Suppresses Myogenin-dependent Atrogene Activation in Spinal Muscular Atrophy Mice

Overview

Journal Hum Mol Genet

Specialties Genetics
Molecular Biology

Date 2012 Jul 17

PMID 22798624

Citations 40

Authors

Katherine V Bricceno

Paul J Sampognaro

James P Van Meerbeke

Charlotte J Sumner

Kenneth H Fischbeck

Barrington G Burnett

Affiliations

Soon will be listed here.

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by mutations in the survival of motor neuron 1 (SMN1) gene and deficient expression of the ubiquitously expressed SMN protein. Pathologically, SMA is characterized by motor neuron loss and severe muscle atrophy. During muscle atrophy, the E3 ligase atrogenes, atrogin-1 and muscle ring finger 1 (MuRF1), mediate muscle protein breakdown through the ubiquitin proteasome system. Atrogene expression can be induced by various upstream regulators. During acute denervation, they are activated by myogenin, which is in turn regulated by histone deacetylases 4 and 5. Here we show that atrogenes are induced in SMA model mice and in SMA patient muscle in association with increased myogenin and histone deacetylase-4 (HDAC4) expression. This activation during both acute denervation and SMA disease progression is suppressed by treatment with a histone deacetylase inhibitor; however, this treatment has no effect when atrogene induction occurs independently of myogenin. These results indicate that myogenin-dependent atrogene induction is amenable to pharmacological intervention with histone deacetylase inhibitors and help to explain the beneficial effects of these agents on SMA and other denervating diseases.

Citing Articles

SMN depletion impairs skeletal muscle formation and maturation in a mouse model of SMA.

Liu H, Chehade L, Deguise M, De Repentigny Y, Kothary R Hum Mol Genet. 2024; 34(1):21-31.

PMID: 39505369 PMC: 11756284. DOI: 10.1093/hmg/ddae162.

Ubiquitination Insight from Spinal Muscular Atrophy-From Pathogenesis to Therapy: A Muscle Perspective.

Bolado-Carrancio A, Tapia O, Rodriguez-Rey J Int J Mol Sci. 2024; 25(16).

PMID: 39201486 PMC: 11354275. DOI: 10.3390/ijms25168800.

MicroRNAs and their Modulatory Effect on the Hallmarks of Osteosarcopenia.

Silva W, Cruz A, Duque G Curr Osteoporos Rep. 2024; 22(5):458-470.

PMID: 39162945 DOI: 10.1007/s11914-024-00880-4.

Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy.

Lumpkin C, Harris A, Connell A, Kirk R, Whiting J, Saieva L Sci Rep. 2023; 13(1):10374.

PMID: 37365234 PMC: 10293174. DOI: 10.1038/s41598-023-37496-0.

Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice.

Boido M, Gesmundo I, Caretto A, Pedrolli F, Schellino R, Leone S Proc Natl Acad Sci U S A. 2023; 120(2):e2216814120.

PMID: 36603028 PMC: 9926281. DOI: 10.1073/pnas.2216814120.

References

Monani U, Lorson C, Parsons D, Prior T, Androphy E, Burghes A . A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999; 8(7):1177-83. DOI: 10.1093/hmg/8.7.1177. View

Stitt T, Drujan D, Clarke B, Panaro F, Timofeyva Y, Kline W . The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004; 14(3):395-403. DOI: 10.1016/s1097-2765(04)00211-4. View

Rose Jr F, Mattis V, Rindt H, Lorson C . Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2008; 18(6):997-1005. PMC: 2649020. DOI: 10.1093/hmg/ddn426. View

Lee Y, Mikesh M, Smith I, Rimer M, Thompson W . Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev Biol. 2011; 356(2):432-44. PMC: 3143211. DOI: 10.1016/j.ydbio.2011.05.667. View

Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P . FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007; 6(6):458-71. DOI: 10.1016/j.cmet.2007.11.001. View

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A . Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117(3):399-412. PMC: 3619734. DOI: 10.1016/s0092-8674(04)00400-3. View

Bodine S, Latres E, Baumhueter S, Lai V, Nunez L, Clarke B . Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-8. DOI: 10.1126/science.1065874. View

Solomon V, Baracos V, Sarraf P, GOLDBERG A . Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. Proc Natl Acad Sci U S A. 1998; 95(21):12602-7. PMC: 22877. DOI: 10.1073/pnas.95.21.12602. View

Avila A, Burnett B, Taye A, Gabanella F, Knight M, Hartenstein P . Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007; 117(3):659-71. PMC: 1797603. DOI: 10.1172/JCI29562. View

10.

Yoo Y, Ko C . Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2011; 231(1):147-59. DOI: 10.1016/j.expneurol.2011.06.003. View

11.

Butchbach M, Rose Jr F, Rhoades S, Marston J, McCrone J, Sinnott R . Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun. 2009; 391(1):835-40. PMC: 2839161. DOI: 10.1016/j.bbrc.2009.11.148. View

12.

Cai D, Frantz J, Tawa Jr N, Melendez P, Oh B, Lidov H . IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004; 119(2):285-98. DOI: 10.1016/j.cell.2004.09.027. View

13.

Kong L, Wang X, Choe D, Polley M, Burnett B, Bosch-Marce M . Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci. 2009; 29(3):842-51. PMC: 2746673. DOI: 10.1523/JNEUROSCI.4434-08.2009. View

14.

Baehr L, Furlow J, Bodine S . Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. J Physiol. 2011; 589(Pt 19):4759-76. PMC: 3213422. DOI: 10.1113/jphysiol.2011.212845. View

15.

Kariya S, Park G, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz M . Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet. 2008; 17(16):2552-69. PMC: 2722888. DOI: 10.1093/hmg/ddn156. View

16.

Millino C, Fanin M, Vettori A, Laveder P, Mostacciuolo M, Angelini C . Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med. 2009; 7:14. PMC: 2676312. DOI: 10.1186/1741-7015-7-14. View

17.

Tang H, MacPherson P, Marvin M, Meadows E, Klein W, Yang X . A histone deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. Mol Biol Cell. 2008; 20(4):1120-31. PMC: 2642751. DOI: 10.1091/mbc.e08-07-0759. View

18.

Tischler M, Rosenberg S, Satarug S, Henriksen E, Kirby C, Tome M . Different mechanisms of increased proteolysis in atrophy induced by denervation or unweighting of rat soleus muscle. Metabolism. 1990; 39(7):756-63. DOI: 10.1016/0026-0495(90)90113-q. View

19.

Rindt H, Buckley D, Vale S, Krogman M, Rose Jr F, Garcia M . Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscul Disord. 2011; 22(3):277-85. DOI: 10.1016/j.nmd.2011.10.012. View

20.

Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1):155-65. DOI: 10.1016/0092-8674(95)90460-3. View